Issues in pediatric haemophilia care
- PMID: 23601343
- PMCID: PMC3651319
- DOI: 10.1186/1824-7288-39-24
Issues in pediatric haemophilia care
Abstract
The hemophilias are the most common X-linked inherited bleeding disorders. The challenges in children are different from that in adults and, If not properly managed, can lead to chronic disease and lifelong disabilities. Currently, inhibitors are the most severe complication and prophylaxis is emerging as the optimal preventive care strategy. Quality of life has become in the western countries the primary objective of the process of providing care, thus all the strategies (psychotherapy, physiotherapy, community life), not just the infusion of the missing factor, should be activated for the patient and family to give them the perception of being healthy.
Similar articles
-
History of prophylaxis.Haemophilia. 2013 Mar;19(2):163-5. doi: 10.1111/hae.12100. Haemophilia. 2013. PMID: 23419107 No abstract available.
-
Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.J Thromb Haemost. 2017 Dec;15(12):2461-2465. doi: 10.1111/jth.13867. Epub 2017 Nov 9. J Thromb Haemost. 2017. PMID: 29119666 No abstract available.
-
A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.Haemophilia. 2012 Jul;18(4):561-7. doi: 10.1111/j.1365-2516.2011.02741.x. Epub 2012 Jan 5. Haemophilia. 2012. PMID: 22221939
-
Diagnosis and treatment of congenital hemophilia with inhibitors a Latin American perspective.Medicina (B Aires). 2008;68(3):227-42. Medicina (B Aires). 2008. PMID: 18689157 Review.
-
[Prophylaxis in patients with haemophilia complicated by inhibitors].Pol Merkur Lekarski. 2011 Mar;30(177):211-4. Pol Merkur Lekarski. 2011. PMID: 21545000 Review. Polish.
Cited by
-
The impact of extended half-life versus conventional factor product on hemophilia caregiver burden.Qual Life Res. 2018 May;27(5):1335-1345. doi: 10.1007/s11136-018-1792-9. Epub 2018 Feb 1. Qual Life Res. 2018. PMID: 29392598 Free PMC article.
-
BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B.Ther Adv Hematol. 2014 Oct;5(5):168-80. doi: 10.1177/2040620714550573. Ther Adv Hematol. 2014. PMID: 25324957 Free PMC article. Review.
-
Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.Front Med (Lausanne). 2019 Dec 3;6:261. doi: 10.3389/fmed.2019.00261. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31850352 Free PMC article. Review.
-
Eligibility for competitive sport medical certification of children with severe hemophilia: Italian observational study.Acta Biomed. 2022 Mar 14;93(1):e2022129. doi: 10.23750/abm.v93i1.11531. Acta Biomed. 2022. PMID: 35315416 Free PMC article.
-
Analysis of Sasang Constitutional Medicine as an Optimal Preventive Care Strategy for Hemophilia Patients.Biomed Res Int. 2020 Feb 1;2020:4147803. doi: 10.1155/2020/4147803. eCollection 2020. Biomed Res Int. 2020. PMID: 32090089 Free PMC article.
References
-
- Pipe SW. Recombinant clotting factors. Thromb Haemost. 2008;99:840–850. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical